Efficacy and safety of revefenacin for nebulization in patients with chronic obstructive pulmonary disease taking concomitant ICS/LABA or LABA: subgroup analysis from phase III trials

BACKGROUND: Combinations of a long-acting muscarinic receptor antagonist (LAMA), long-acting β-agonist (LABA), and inhaled corticosteroid (ICS) are used for patients with persistent chronic obstructive pulmonary disease (COPD) exacerbations on bronchodilator monotherapy. In this prespecified subgrou...

Descripción completa

Detalles Bibliográficos
Autores principales: Sethi, Sanjay, Donohue, James F., Ferguson, Gary T., Barnes, Chris N., Crater, Glenn D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7052452/
https://www.ncbi.nlm.nih.gov/pubmed/32106777
http://dx.doi.org/10.1177/1753466620905278

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7052452/
https://www.ncbi.nlm.nih.gov/pubmed/32106777
http://dx.doi.org/10.1177/1753466620905278

Ejemplares similares